No adverse event; patient received dose of the Bivalent Moderna COVID-19 vaccine as booster dose after the 30 day beyond use date, patient administered EXPIRED dose of the Moderna COVID-19 vaccine bivalent as booster dose; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (patient received dose of the Bivalent Moderna COVID-19 vaccine as booster dose after the 30 day beyond use date, patient administered EXPIRED dose of the Moderna COVID-19 vaccine bivalent as booster dose) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 059F22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 17-Jan-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .5 milliliter. On 17-Jan-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (patient received dose of the Bivalent Moderna COVID-19 vaccine as booster dose after the 30 day beyond use date, patient administered EXPIRED dose of the Moderna COVID-19 vaccine bivalent as booster dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (patient received dose of the Bivalent Moderna COVID-19 vaccine as booster dose after the 30 day beyond use date, patient administered EXPIRED dose of the Moderna COVID-19 vaccine bivalent as booster dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (patient received dose of the Bivalent Moderna COVID-19 vaccine as booster dose after the 30 day beyond use date, patient administered EXPIRED dose of the Moderna COVID-19 vaccine bivalent as booster dose).    Concomitant drugs were not reported. It was reported that patient was administered with expired doses of the Moderna COVID-19 vaccine bivalent as booster dose. Treatment medications were not provided. This case was reported for patient 1 out of 17 patients.   This case was linked to MODERNATX, INC.-MOD-2023-699155, MODERNATX, INC.-MOD-2023-699156, MODERNATX, INC.-MOD-2023-699157, MODERNATX, INC.-MOD-2023-699158, MODERNATX, INC.-MOD-2023-699160, MODERNATX, INC.-MOD-2023-699161, MODERNATX, INC.-MOD-2023-699162, MODERNATX, INC.-MOD-2023-699163, MODERNATX, INC.-MOD-2023-699172, MODERNATX, INC.-MOD-2023-699176, MODERNATX, INC.-MOD-2023-699177, MODERNATX, INC.-MOD-2023-699187, MODERNATX, INC.-MOD-2023-699188, MODERNATX, INC.-MOD-2023-699190, MODERNATX, INC.-MOD-2023-699195, MODERNATX, INC.-MOD-2023-699191 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 19-Jan-2023: Live Non Significant Follow up received, no new information were added.; Sender's Comments:  MODERNATX, INC.-MOD-2023-699160: MODERNATX, INC.-MOD-2023-699157: MODERNATX, INC.-MOD-2023-699156: MODERNATX, INC.-MOD-2023-699158: MODERNATX, INC.-MOD-2023-699161: MODERNATX, INC.-MOD-2023-699155: MODERNATX, INC.-MOD-2023-699191: MODERNATX, INC.-MOD-2023-699190: MODERNATX, INC.-MOD-2023-699187: MODERNATX, INC.-MOD-2023-699177: MODERNATX, INC.-MOD-2023-699176: MODERNATX, INC.-MOD-2023-699195: MODERNATX, INC.-MOD-2023-699163: MODERNATX, INC.-MOD-2023-699162: MODERNATX, INC.-MOD-2023-699188: MODERNATX, INC.-MOD-2023-699172: